[eDisclosure Notice] Daewoong Pharmaceutical, Approval of Type 2 Diabetes Treatment by MFDS, etc. (Morning Summary)

[Asia Economy Reporter Kwon Jaehee] Daewoong Pharmaceutical announced on the 1st that it has received domestic product approval from the Ministry of Food and Drug Safety for the type 2 diabetes treatment 'DWP16001 (SGLT2 inhibitor)'. The following are the major disclosures released that morning.

▲ Samsung Electronics = Disclosed that it donated 18.37 billion KRW to the 'Hope 2023 Sharing Campaign' fundraising by the Community Chest of Korea, a social welfare foundation. The company stated, "We contributed donations to the fundraising to share warmth with marginalized groups and fulfill corporate social responsibility."

▲ HuSteel = Announced on the 1st that the issuance price of new shares for the rights offering was set at 3,965 KRW. The new shares amount to 17 million common shares.

▲ Daesang Holdings = Signed a letter of intent for investment to establish a joint venture with Sinopharm International (China National Pharmaceutical Group Co., Ltd.), a subsidiary of Sinopharm, to enter the Chinese market through its subsidiary Daesang Wellife.

▲ DL Construction = Announced on the 1st that it signed a contract to build a logistics center in Bukjeong-dong, Yangsan City, worth 140.2 billion KRW with Capital Land Korea No.14 Real Estate Private Investment Company. This amount corresponds to 11.94% of the 2021 sales revenue.

▲ Samsung Electronics = Announced on the 1st that it decided to donate approximately 9.56767 billion KRW, combining the proceeds and donations generated from the 'Samsung Global Goals' app, in partnership with UNDP to participate in achieving the UN's global goals.

▲ Samsung Electronics = Announced on the 1st that it will sponsor 1.65 million euros (approximately 2.25 billion KRW) for the International Skills Olympics to nurture future technology talents contributing to global industrial development.

This content was produced with the assistance of AI translation services.